Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | XPO1 | O14980 | 2/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857395 | 0.83 | HDAC3 (0.40) | KMT2APOLB | |
| SCHEMBL29223296 | 0.82 | LMNA (0.40) | LMNAKMT2AMAPKAPK2MTNR1AMTNR1B | |
| SCHEMBL27647823 | 0.80 | HTT (0.38) | LMNAKMT2AHTTAAK1XPO1 | |
| SCHEMBL28001487 | 0.79 | RXRA (0.43) | HTTXPO1RXRAP2RX7 | |
| SCHEMBL855385 | 0.79 | XPO1 (0.43) | LMNAHTTPOLBCACNA1BCACNA1C | |
| SCHEMBL27627608 | 0.76 | NOTUM (0.39) | LMNAKMT2AHTTXPO1 | |
| SCHEMBL11974014 | 0.72 | XPO1 (0.36) | HTTCACNA1CXPO1 | |
| SCHEMBL17477208 | 0.72 | NOTUM (0.37) | HTTXPO1P2RX7 | |
| SCHEMBL2212160 | 0.71 | ACACB (0.41) | KMT2AHTTMTNR1AMTNR1B | |
| SCHEMBL991391 | 0.71 | MTNR1A (0.40) | LMNACACNA1BCACNA1CCACNA1HAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060058356-A1 | Indolylmaleimide derivatives | NOVARTIS AG | 2006-03-16 | — | — | US | disclosed |
| EP-1597250-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058356-A1 | Indolylmaleimide derivatives | GSK3B, GSK3A, GSKIP | LMNA 1298/4885KMT2A 1839/4885HTT 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.